DOI: https://doi.org/10.22263/2312-4156.2017.5.31
Makarenko E.V.
Giant cell arteritis. Part II
Vitebsk State Order of Peoples’ Friendship Medical University, Vitebsk, Republic of Belarus
Vestnik VGMU. 2017;16(5):31-39.
Abstract.
The basis for the therapy of giant cell arteritis is glucocorticosteroids. To reduce the risk of complications associated with their use, immunosuppressive therapy with methotrexate may be used. In 2016 recommendations for the management of patients with giant cell arteritis, elaborated by the French Research Group for the Study of Vasculitis of Large Vessels (Groupe d’Étude Frances ais des Artérites des grosvaisseaux, GEFA), were published. They concern the nomenclature of the disease, the classification criteria of giant cell arteritis, the role of temporal artery biopsy and imaging methods in the diagnosis of this pathology, the methods used for detecting aorta and its branches lesions, the mode of glucocorticosteroids administration, the treatment of giant cell arteritis complications, indications for the use of immunosuppressants or targeted biotherapy as well as the management of patients with exacerbations and relapses.
Key words: giant cell arteritis, temporal arteritis, treatment, recommendations.
References
1. Hoffman GS. Giant Cell Arteritis / G. S. Hoffman. Ann Intern Med. 2016 Nov;165(9):ITC65-ITC80. doi: http://dx.doi.org/10.7326/AITC201611010
2. Dasgupta B, Borg FA, Hassan N, Alexander L, Barraclough K, Bourke B, Fulcher J, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010 Aug;49(8):1594-7. doi: http://dx.doi.org/10.1093/rheumatology/keq039a
3. Nesher G, Breuer GS. Giant Cell Arteritis and Polymyalgia Rheumatica: 2016 Update. Rambam Maimonides Med J. 2016 Oct;7(4). doi: http://dx.doi.org/10.5041/RMMJ.10262
4. Frohman L, Wong AB, Matheos K, Leon-Alvarado LG, Danesh-Meyer HV. New developments in giant cell arteritis. Surv Ophthalmol. 2016 Jul-Aug;61(4):400-21. doi: http://dx.doi.org/10.1016/j.survophthal.2016.01.001
5. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009 Mar;68(3):318-23. doi: http://dx.doi.org/10.1136/ard.2008.088351
6. Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002 May;46(5):1309-18. doi: http://dx.doi.org/10.1002/art.10262
7. Nesher G, Nesher R, Mates M, Sonnenblick M, Breuer GS. Giant cell arteritis: intensity of the initial systemic inflammatory response and the course of the disease. Clin Exp Rheumatol. 2008 May-Jun;26(3 Suppl 49):S30-4.
8. Ungprasert P, Koster MJ, Warrington KJ. Coronary artery disease in giant cell arteritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2015 Apr;44(5):586-591. doi: http://dx.doi.org/10.1016/j.semarthrit.2014.10.010
9. Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 2004 Apr;50(4):1332-7. doi: http://dx.doi.org/10.1002/art.20171
10. Lee MS, Smith SD, Galor A, Hoffman GS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum. 2006 Oct;54(10):3306-9. doi: http://dx.doi.org/10.1002/art.22141
11. Nesher G. The diagnosis and classification of giant cell arteritis. J Autoimmun. 2014 Feb-Mar;48-49:73-5. doi: http://dx.doi.org/10.1016/j.jaut.2014.01.017
12. Mahr AD, Jover JA, Spiera RF, Hernández-García C, Fernández-Gutiérrez B, Lavalley MP, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007 Aug;56(8):2789-97. doi: http://dx.doi.org/10.1002/art.22754
13. Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003 Oct;49(5):703-8. doi: http://dx.doi.org/10.1002/art.11388
14. Sciascia S, Piras D, Baldovino S, Russo A, Naretto C, Rossi D, Alpa M, et al. Mycophenolate mofetil as steroid-sparing treatment for elderly patients with giant cell arteritis: report of three cases. Aging Clin Exp Res. 2012 Jun;24(3):273-7.
15. Caporali R, Cimmino MA, Ferraccioli G, Gerli R, Klersy C, Salvarani C, et al. Prednisone plus methotrexate for polymyalgia rheumatica:a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2004 Oct;141(7):493-500.
16. Jover JA, Hernández-García C, Morado IC, Vargas E, Bañares A, Fernández-Gutiérrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001 Jan;134(2):106-14.
17. De Silva M, Hazleman BL. Azathioprine in giant cell arteritis/polymyalgiarheumatica: a double-blind study. Ann Rheum Dis. 1986 Feb;45(2):136-8.
18. Meshkov AD, Novikov PI, Fomin VV, Moiseev SV. Giant cell arteritis: difficulties in diagnosis and treatment methods. Klin Farmakologiia Terapiia. 2014;23(2):48-54. (In Russ.)
19. Lourdudoss C, Vollenhoven Rv. Mycophenolate mofetil in the treatment of SLE and systemic vasculitis: experience at a single university center. Lupus. 2014 Mar;23(3):299-304. doi: http://dx.doi.org/10.1177/0961203313519158
20. Hu W, Liu C, Xie H, Chen H, Liu Z, Li L. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement. Nephrol Dial Transplant. 2008 Apr;23(4):1307-12. doi: http://dx.doi.org/10.1093/ndt/gfm780
21. Sciascia S, Piras D, Baldovino S, Russo A, Naretto C, Rossi D, et al. Mycophenolate mofetil as steroid-sparing treatment for elderly patients with giant cell arteritis: report of three cases. Aging Clin Exp Res. 2012 Jun;24(3):273-7.
22. de Vita S, Tavoni A, Jeracitano G, Gemignani G, Dolcher MP, Bombardieri S. Treatment of giant cell arteritis with cyclophosphamide pulses. J Intern Med. 1992 Oct;232(4):373-5.
23. Loock J, Henes J, Kötter I, Witte T, Lamprecht P, Schirmer M, et al. Treatment of refractory giant cell arteritis with cyclophosphamide: a retrospective analysis of 35 patients from three centres. Clin Exp Rheumatol. 2012 Jan-Feb;30(1 Suppl 70):S70-6
24. Quartuccio L, Maset M, De Maglio G, Pontarini E, Fabris M, Mansutti E, et al. Role of oral cyclophosphamide in the treatment of giant cell arteritis. Rheumatology (Oxford). 2012 Sep;51(9):1677-86. doi: http://dx.doi.org/10.1093/rheumatology/kes127
25. Adizie T, Christidis D, Dharmapaliah C, Borg F, Dasgupta B. Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series. Int J Clin Pract. 2012 Sep;66(9):906-9. doi: http://dx.doi.org/10.1111/j.1742-1241.2012.02981.x
26. Diamantopoulos AP, Hetland H, Myklebust G. Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series. Biomed Res Int. 2013;2013:120638. doi: http://dx.doi.org/10.1155/2013/120638
27. Ahmed MM, Mubashir E, Hayat S, Fowler M, Berney SM. Treatment of refractory temporal arteritis with adalimumab. Clin Rheumatol. 2007 Aug;26(8):1353-5. doi: http://dx.doi.org/10.1007/s10067-006-0375-2
28. Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, et al. Tocilizumab for induction and maintenance of remission in giant cellarteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016 May;387(10031):1921-7.
29. Bhatia A, Ell PJ, Edwards JC. Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis. 2005 Jul;64(7):1099-100. doi: http://dx.doi.org/10.1136/ard.2005.036533
30. Fernández-Fernández FJ. Might pentoxifylline have a role as adjuvant therapy for patients with giant cell arteritis? Drugs Aging. 2011 Oct;28(10):847. doi: http://dx.doi.org/10.2165/11596480-000000000-00000
31. Moller DR, Wysocka M, Greenlee BM, Ma X, Wahl L, Trinchieri G, Karp CL. Inhibition of human interleukin-12 production by pentoxifylline. Immunology. 1997;91(2):197-203.
32. Bienvenu B, Ly KH, Lambert M, Agard C, André M, Benhamou Y, et al. Management of giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA). Rev Med Interne. 2016 Mar;37(3):154-65. doi: http://dx.doi.org/10.1016/j.revmed.2015.12.015
Information about authors:
Makarenko E.V. – Doctor of Medical Sciences, professor of the Chair of Internal Medicine No. 2 of the Faculty for Advanced Training & Retraining, Vitebsk State Order of Peoples’ Friendship Medical University.
Correspondence address: Republic of Belarus, 210023, Vitebsk, 27 Frunze ave., Vitebsk State Order of Peoples’ Friendship Medical University, Chair of Internal Medicine No. 2 of the Faculty for Advanced Training & Retraining. E-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра. – Elena V. Makarenko.
